Analysts’ Viewpoint on Global Atrial Fibrillation Market Scenario
Hypertension and obesity are the leading causes of cardiovascular disorders, especially atrial fibrillation. The prevalence of these disorders is rising due to socio-economic factors such as lifestyle-induced dietary and other habits, including excessive alcohol consumption and smoking. Moreover, supporting the market growth is the rising geriatric population globally, as the risk of atrial fibrillation is higher in this group of people. Favorable results exhibited by clinical trials pertaining to combined pharmacological therapy are likely to drive the global atrial fibrillation market, by catering to the unmet medical needs prevalent in the field of atrial fibrillation. Companies are undertaking more such trials to provide better treatment option for those suffering from atrial fibrillation. The global market is also anticipated to be driven by the introduction of advanced treatment procedures such as hybrid ablation and rise in prevalence of atrial fibrillation in emerging economies of Asia.
Atrial fibrillation refers to a type of cardiac arrhythmia distinguished by an abnormal cardiac rhythm caused by a disturbance in heart’s electrical system. Atrial fibrillation (AF) is one of the most commonly occurring cardiac rhythm conditions. Being a potentially life threatening disease and expensive to treat, the overall healthcare system views the treatment for this condition as a strategically critical area to address. Increase in global geriatric population is a key factor projected to drive the global atrial fibrillation market during the forecast period.
Cardiovascular disorders, especially atrial fibrillation, are most times a result of hypertension and obesity. According to the Framingham Heart Study, 14% of the atrial fibrillation risks were associated with hypertension, and obesity increased the risk of progression of paroxysmal atrial fibrillation to permanent atrial fibrillation by 45% to 50%. The prevalence of these disorders is rising due to socio-economic factors such as lifestyle induced dietary and other habits (excessive alcohol consumption and smoking).
According to WHO estimates, 35% of adults aged 20 years and above were overweight. The global prevalence of obesity has almost doubled since 1980 and is expected to rapidly increase in future. Moreover, the prevalence of hypertension in 2008 was stood at 1 billion. The WHO suggests that in 2008, the prevalence of hypertension in low, middle, and upper middle income countries was 40% and 35% in high income countries. High and rise in prevalence of these disorders is expected to propel the global atrial fibrillation market during the forecast period.
The combined pharmacological therapy is a new and promising treatment option for atrial fibrillation. The combined pharmacological therapy has exhibited encouraging results in clinical trials and would help in catering to the unmet medical needs in those suffering from atrial fibrillation. This factor is projected to drive the global atrial fibrillation market. Additionally, research results on animal mode for the combined therapy yielded favorable and synergistic anti-arrhythmic results.
The clinical trials aimed at testing the effect of a combined therapy involving Multaq and Ranexa was unveiled at the Boston Atrial Fibrillation Symposium. This clinical trial was titled HARMONY and enrolled around 150 patients with non-permanent atrial fibrillation and with implanted pacemakers. Preclinical data revealed by this study suggest that this combination therapy is well positioned in the current anti-arrhythmic drugs segment, especially on the grounds of safety and efficacy.
Atrial fibrillation devices such as implantable pacemakers, defibrillators, and catheters are regarded as class III high risk medical devices by the U.S. FDA. Therefore, these devices undergo rigorous safety and efficacy tests prior to receiving an approval. Moreover, these devices need to obtain a premarket approval, which is an expensive and lengthy affair. Atrial fibrillation drugs are no exception to these stringent regulations and hence, need to undergo strictly monitored safety and efficacy tests. Failure to comply with the regulations laid down by the FDA and European Medicines Agency will result in a product recall or clinical trial termination. For instance, termination of PALLAS study and issuance of safety alerts by the FDA for Multaq.
Surge in global geriatric population increases the incidence rate of atrial fibrillation. This acts as a major driver for the global atrial fibrillation market. Additionally, favorable results exhibited by clinical trials promoting combined pharmacological therapy such as the HARMONY trial and rise in prevalence of disorders causing atrial fibrillation such as hypertension and obesity are projected to propel the global atrial fibrillation market.
In terms of product type, the global atrial fibrillation market has been bifurcated into pharmacological treatment and non-pharmacological treatment. The pharmacological treatment segment accounted for a leading share of the global market in 2021. The pharmacological treatment procedures are administered more frequently to patients suffering from atrial fibrillation, and are a cheaper alternative to non-pharmacological procedures. The pharmacological treatment procedures segment is expected to gain market share due to the introduction of new drugs such as Bristol Myer Squibb’s NTC-801, Merck’s Vernakalant, and Boehringer Ingelheim’s Pradaxa.
In terms of region, the global atrial fibrillation market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global atrial fibrillation market in 2021, followed by Europe.
North America is a leading market for atrial fibrillation due to high prevalence of atrial fibrillation, high disposable income of patients, and sophisticated healthcare infrastructure. Emerging markets in Asia Pacific exhibit immense growth potential due to initiatives taken by governments to promote healthcare and robust economic growth. Moreover, improving purchasing power, consumer awareness about health issues, and better disease management are likely to fuel the growth of the atrial fibrillation market in Asia Pacific.
This report profiles key players in the global atrial fibrillation market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global atrial fibrillation market is highly fragmented, with the presence of a number of international as well as regional players. Leading players operating in the global atrial fibrillation market are AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, St. Jude Medical, Inc., and Johnson & Johnson Ltd, among others.
Key players in the global atrial fibrillation market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global atrial fibrillation market. A few expansion strategies adopted by players operating in the global atrial fibrillation market are:
| Attribute | Detail |
|---|---|
| Market Size Value in 2021 | US$ 10.2 Bn |
| Market Forecast Value in 2031 | US$ 18.5 Bn |
| Growth Rate (CAGR) | 6% |
| Forecast Period | 2022-2031 |
| Historical Data Available for | 2017-2020 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global atrial fibrillation market was valued at US$ 10.2 Bn in 2021.
The global atrial fibrillation market is expected to surpass US$ 18.5 Bn by 2031.
The global atrial fibrillation market is anticipated to record a CAGR of 6% from 2022 to 2031.
Increase in incidence of atrial fibrillation due to rise in prevalence of disorders such as hypertension and obesity positively impact the global market
The pharmacological treatment segment held over 54% share of the global atrial fibrillation market in 2021.
North America is expected to be a potential revenue generator for vendors during the forecast period.
Prominent players in the global atrial fibrillation market include AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, St. Jude Medical, Inc. and Johnson and Johnson Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Atrial Fibrillation Market
4. Market Overview
4.1. Introduction
4.1.1. Treatment Type Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Atrial Fibrillation Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Developments
5.2. Disease Prevalence & Incidence Rate, by Region/Globally
5.3. Atrial Fibrillation Overview
5.4. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
6. Global Atrial Fibrillation Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment Type, 2017-2031
6.3.1. Pharmacological Treatment
6.3.1.1. Anti-arrhythmic Drugs
6.3.1.2. Anti-coagulant Drugs
6.3.2. Non-pharmacological Treatment
6.3.2.1. Catheter Ablation
6.3.2.1.1. Radiofrequency Based
6.3.2.1.2. Cryoablation Based
6.3.2.1.3. HIFU (High Intensity Focused Ultrasound) Based
6.3.2.1.4. Microwave Based
6.3.2.1.5. Laser Based
6.3.2.2. Maze Surgery
6.3.2.3. Electric Cardioversion
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Atrial Fibrillation Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Market Value Forecast, by Region
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness Analysis, by Region
8. North America Atrial Fibrillation Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by Treatment Type, 2017-2031
8.2.1. Pharmacological Treatment
8.2.1.1. Anti-arrhythmic Drugs
8.2.1.2. Anti-coagulant Drugs
8.2.2. Non-pharmacological Treatment
8.2.2.1. Catheter Ablation
8.2.2.1.1. Radiofrequency Based
8.2.2.1.2. Cryoablation Based
8.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based
8.2.2.1.4. Microwave Based
8.2.2.1.5. Laser Based
8.2.2.2. Maze Surgery
8.2.2.3. Electric Cardioversion
8.3. Market Value Forecast, by Country, 2017-2031
8.3.1. U.S.
8.3.2. Canada
8.4. Market Attractiveness Analysis
8.4.1. By Treatment Type
8.4.2. By Country
9. Europe Atrial Fibrillation Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2017-2031
9.2.1. Pharmacological Treatment
9.2.1.1. Anti-arrhythmic Drugs
9.2.1.2. Anti-coagulant Drugs
9.2.2. Non-pharmacological Treatment
9.2.2.1. Catheter Ablation
9.2.2.1.1. Radiofrequency Based
9.2.2.1.2. Cryoablation Based
9.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based
9.2.2.1.4. Microwave Based
9.2.2.1.5. Laser Based
9.2.2.2. Maze Surgery
9.2.2.3. Electric Cardioversion
9.3. Market Value Forecast, by Country/Sub-region, 2017-2031
9.3.1. Germany
9.3.2. U.K.
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Market Attractiveness Analysis
9.4.1. By Treatment Type
9.4.2. By Country/Sub-region
10. Asia Pacific Atrial Fibrillation Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017-2031
10.2.1. Pharmacological Treatment
10.2.1.1. Anti-arrhythmic Drugs
10.2.1.2. Anti-coagulant Drugs
10.2.2. Non-pharmacological Treatment
10.2.2.1. Catheter Ablation
10.2.2.1.1. Radiofrequency Based
10.2.2.1.2. Cryoablation Based
10.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based
10.2.2.1.4. Microwave Based
10.2.2.1.5. Laser Based
10.2.2.2. Maze Surgery
10.2.2.3. Electric Cardioversion
10.3. Market Value Forecast, by Country/Sub-region, 2017-2031
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Australia & New Zealand
10.3.5. Rest of Asia Pacific
10.4. Market Attractiveness Analysis
10.4.1. By Treatment Type
10.4.2. By Country/Sub-region
11. Latin America Atrial Fibrillation Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017-2031
11.2.1. Pharmacological Treatment
11.2.1.1. Anti-arrhythmic Drugs
11.2.1.2. Anti-coagulant Drugs
11.2.2. Non-pharmacological Treatment
11.2.2.1. Catheter Ablation
11.2.2.1.1. Radiofrequency Based
11.2.2.1.2. Cryoablation Based
11.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based
11.2.2.1.4. Microwave Based
11.2.2.1.5. Laser Based
11.2.2.2. Maze Surgery
11.2.2.3. Electric Cardioversion
11.3. Market Value Forecast, by Country/Sub-region, 2017-2031
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Market Attractiveness Analysis
11.4.1. By Treatment Type
11.4.2. By Country/Sub-region
12. Middle East & Africa Atrial Fibrillation Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017-2031
12.2.1. Pharmacological Treatment
12.2.1.1. Anti-arrhythmic Drugs
12.2.1.2. Anti-coagulant Drugs
12.2.2. Non-pharmacological Treatment
12.2.2.1. Catheter Ablation
12.2.2.1.1. Radiofrequency Based
12.2.2.1.2. Cryoablation Based
12.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based
12.2.2.1.4. Microwave Based
12.2.2.1.5. Laser Based
12.2.2.2. Maze Surgery
12.2.2.3. Electric Cardioversion
12.3. Market Value Forecast, by Country/Sub-region, 2017-2031
12.3.1. GCC Countries
12.3.2. South Africa
12.3.3. Rest of Middle East & Africa
12.4. Market Attractiveness Analysis
12.4.1. By Treatment Type
12.4.2. By Country/Sub-region
13. Competition Landscape
13.1. Market Player - Competition Matrix (by tier and size of companies)
13.2. Company Profiles
13.2.1. Agilent Technologies, Inc.
13.2.1.1. Company Overview
13.2.1.2. Business Overview
13.2.1.3. Financial Overview
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.2. Allied Healthcare Products, Inc.
13.2.2.1. Company Overview
13.2.2.2. Business Overview
13.2.2.3. Financial Overview
13.2.2.4. SWOT Analysis
13.2.2.5. Strategic Overview
13.2.3. CareFusion Corporation
13.2.3.1. Company Overview
13.2.3.2. Business Overview
13.2.3.3. Financial Overview
13.2.3.4. SWOT Analysis
13.2.3.5. Strategic Overview
13.2.4. Covidien plc
13.2.4.1. Company Overview
13.2.4.2. Business Overview
13.2.4.3. Financial Overview
13.2.4.4. SWOT Analysis
13.2.4.5. Strategic Overview
13.2.5. GE Healthcare Ltd.
13.2.5.1. Company Overview
13.2.5.2. Business Overview
13.2.5.3. Financial Overview
13.2.5.4. SWOT Analysis
13.2.5.5. Strategic Overview
13.2.6. GF Health Products, Inc.
13.2.6.1. Company Overview
13.2.6.2. Business Overview
13.2.6.3. Financial Overview
13.2.6.4. SWOT Analysis
13.2.6.5. Strategic Overview
13.2.7. Omron Healthcare, Inc.
13.2.7.1. Company Overview
13.2.7.2. Business Overview
13.2.7.3. Financial Overview
13.2.7.4. SWOT Analysis
13.2.7.5. Strategic Overview
13.2.8. PARI Respiratory Equipment, Inc.
13.2.8.1. Company Overview
13.2.8.2. Business Overview
13.2.8.3. Financial Overview
13.2.8.4. SWOT Analysis
13.2.8.5. Strategic Overview
13.2.9. Philips Healthcare
13.2.9.1. Company Overview
13.2.9.2. Business Overview
13.2.9.3. Financial Overview
13.2.9.4. SWOT Analysis
13.2.9.5. Strategic Overview
List of Table
Table 1: Global Atrial Fibrillation Market Size (US$ Mn) Forecast, 2017-2031
Table 2: Global Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology, 2017-2031
Table 3: Global Atrial Fibrillation Market Size (US$ Mn) Forecast, by Region, 2017-2031
Table 4: North America Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017-2031
Table 5: North America Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country, 2017-2031
Table 6: Europe Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017-2031
Table 7: Europe Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 8: Asia Pacific Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017-2031
Table 9: Asia Pacific Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Latin America Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017-2031
Table 11: Latin America Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Middle East & Africa Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017-2031
Table 13: Middle East & Africa Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
List of Figure
Figure 1: Global Atrial Fibrillation Market Size (US$ Mn) Forecast, 2017-2031
Figure 2: Global Atrial Fibrillation Market Value Share, by Treatment Type, 2021
Figure 3: Global Atrial Fibrillation Market Value Share, by Region, 2021
Figure 4: Global Molecular Diagnostic Market Attractiveness Analysis, by Treatment Type, 2021
Figure 5: Global Pharmacological Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2031
Figure 6: Global Non-pharmacological Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2031
Figure 7: Global Atrial Fibrillation Market Attractiveness Analysis, by Region, 2022-2031
Figure 8: North America Atrial Fibrillation Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 9: North America Atrial Fibrillation Market Attractiveness Analysis, by Country, 2022-2031
Figure 10: North America Market Value Share Analysis, by Technology Type, 2017 and 2031
Figure 11: North America Market Attractiveness Analysis, by Technology Type, 2022 and 2031
Figure 12: North America Market Value Share Analysis, by Country, 2017 and 2031
Figure 13: North America Market Attractiveness Analysis, by Technology, 2022-2031
Figure 14: Europe Atrial Fibrillation Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 15: Europe Atrial Fibrillation Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 16: Europe Market Value Share Analysis, by Technology Type, 2017 and 2031
Figure 17: Europe Market Attractiveness Analysis, by Technology Type, 2017 and 2031
Figure 18: Europe Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 19: Europe Market Attractiveness Analysis, by Technology, 2022-2031
Figure 20: Asia Pacific Atrial Fibrillation Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 21: Asia Pacific Atrial Fibrillation Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 22: Asia Pacific Market Value Share Analysis, by Technology Type, 2017 and 2031
Figure 23: Asia Pacific Market Attractiveness Analysis, by Technology Type, 2017 and 2031
Figure 24: Asia Pacific Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 25: Asia Pacific Market Attractiveness Analysis, by Technology, 2022-2031
Figure 26: Latin America Atrial Fibrillation Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 27: Latin America Atrial Fibrillation Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 28: Latin America Market Value Share Analysis, by Technology Type, 2017 and 2031
Figure 29: Latin America Market Attractiveness Analysis, by Technology Type, 2017 and 2031
Figure 30: Latin America Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 31: Latin America Market Attractiveness Analysis, by Technology, 2022-2031
Figure 32: Middle East & Africa Atrial Fibrillation Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 33: Middle East & Africa Atrial Fibrillation Market Attractiveness Analysis, by Country/Sub-region, 2020
Figure 34: Middle East & Africa Market Value Share Analysis, by Technology Type, 2017 and 2031
Figure 35: Middle East & Africa Market Attractiveness Analysis, by Technology Type, 2017 and 2031
Figure 36: Middle East & Africa Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 37: Middle East & Africa Market Attractiveness Analysis, by Technology, 2022-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Atrial Fibrillation Market
